Skip to main content

Table 3 ODs and ED for (+)-[18F]flubatine based on human data

From: Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results

Target organ

OD

SD

ED contribution

SD

(mSv/MBq)

(mSv/MBq)

Adrenals

1.30E−02

2.26E−03

1.12E−04

1.94E−05

Brain

2.86E−02

3.33E−03

2.86E−04

3.33E−05

Breasts

6.29E−03

3.86E−04

7.55E−04

4.63E−05

Gallbladder wall

2.34E−02

9.30E−03

2.01E−04

7.99E−05

LLI wall

1.67E−02

2.89E−03

1.00E−03

1.74E−04

Small intestine

2.94E−02

8.90E−03

2.53E−04

7.66E−05

Stomach wall

2.04E−02

3.89E−03

2.44E−03

4.67E−04

ULI wall

3.24E−02

1.02E−02

1.94E−03

6.14E−04

Heart wall

1.57E−02

1.65E−03

1.35E−04

1.42E−05

Kidneys

3.81E−02

4.52E−03

3.28E−04

3.89E−05

Liver

5.31E−02

2.98E−02

2.12E−03

1.19E−03

Lungs

2.70E−02

2.60E−03

3.24E−03

3.12E−04

Muscle

7.90E−03

1.26E−04

6.80E−05

1.08E−06

Ovaries

1.31E−02

1.22E−03

1.05E−03

9.73E−05

Pancreas

2.08E−02

4.11E−03

1.79E−04

3.53E−05

Red marrow

1.49E−02

8.50E−04

1.79E−03

1.02E−04

Osteogenic cells

1.42E−02

7.81E−04

1.42E−04

7.81E−06

Skin

5.52E−03

1.27E−04

5.52E−05

1.27E−06

Spleen

1.34E−02

4.19E−03

1.15E−04

3.60E−05

Testes

2.17E−02

1.21E−02

1.53E−03

1.33E−03

Thymus

7.48E−03

2.91E−04

6.43E−05

2.50E−06

Thyroid

2.29E−02

4.37E−03

9.17E−04

1.75E−04

Urinary bladder wall

1.02E−01

2.96E−02

4.09E−03

1.18E−03

Uterus

1.55E−02

1.71E−03

1.33E−04

1.47E−05

Total body

1.05E−02

8.42E−04

ED (mSv/MBq)

  

2.30E−02

1.91E−03

ED (mSv/MBq) ICRP 60

 

2.48E−02

1.18E−03

  1. ODs calculated for the adult male model (73.7 kg, implemented in OLINDA)
  2. OD organ dose, ED effective dose (ICRP 103), SD standard deviation mean over three human subjects